Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence

Emanuele Bertaglia, Benjamin Blank, Carina Blomström-Lundqvist, Axel Brandes, Nuno Cabanelas, G-Andrei Dan, Wolfgang Dichtl, Andreas Goette, Joris R de Groot, Andrzej Lubinski, Eloi Marijon, Béla Merkely, Lluis Mont, Christopher Piorkowski, Andrea Sarkozy, Neil Sulke, Panos Vardas, Vasil Velchev, Dan Wichterle, Paulus Kirchhof, Emanuele Bertaglia, Benjamin Blank, Carina Blomström-Lundqvist, Axel Brandes, Nuno Cabanelas, G-Andrei Dan, Wolfgang Dichtl, Andreas Goette, Joris R de Groot, Andrzej Lubinski, Eloi Marijon, Béla Merkely, Lluis Mont, Christopher Piorkowski, Andrea Sarkozy, Neil Sulke, Panos Vardas, Vasil Velchev, Dan Wichterle, Paulus Kirchhof

Abstract

Self-terminating atrial arrhythmias are commonly detected on continuous rhythm monitoring, e.g. by pacemakers or defibrillators. It is unclear whether the presence of these arrhythmias has therapeutic consequences. We sought to summarize evidence on the prevalence of atrial high-rate episodes (AHREs) and their impact on risk of stroke. We performed a comprehensive, tabulated review of published literature on the prevalence of AHRE. In patients with AHRE, but without atrial fibrillation (AF), we reviewed the stroke risk and the potential risk/benefit of oral anticoagulation. Atrial high-rate episodes are found in 10-30% of AF-free patients. Presence of AHRE slightly increases stroke risk (0.8% to 1%/year) compared with patients without AHRE. Atrial high-rate episode of longer duration (e.g. those >24 h) could be associated with a higher stroke risk. Oral anticoagulation has the potential to reduce stroke risk in patients with AHRE but is associated with a rate of major bleeding of 2%/year. Oral anticoagulation is not effective in patients with heart failure or survivors of a stroke without AF. It remains unclear whether anticoagulation is effective and safe in patients with AHRE. Atrial high-rate episodes are common and confer a slight increase in stroke risk. There is true equipoise on the best way to reduce stroke risk in patients with AHRE. Two ongoing trials (NOAH-AFNET 6 and ARTESiA) will provide much-needed information on the effectiveness and safety of oral anticoagulation using non-vitamin K antagonist oral anticoagulants in patients with AHRE.

Keywords: Anticoagulation; Atrial fibrillation; Atrial high-rate episodes; Continuous monitoring; Pacemaker; Stroke.

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.

Figures

Figure1
Figure1
Percentage of AHRE in patients with (left panel) and without (right panel) known AF. AF, atrial fibrillation; AHRE, atrial high-rate episode.

References

    1. Defaye P, Dournaux F, Mouton E.. Prevalence of supraventricular arrhythmias from the automated analysis of data stored in the DDD pacemakers of 617 patients: the AIDA study. The AIDA Multicenter Study Group. Automatic Interpretation for Diagnosis Assistance. Pacing Clin Electrophysiol 1998;21:250–5.
    1. Todd D, Hernandez-Madrid A, Proclemer A, Bongiorni MG, Estner H, Blomstrom-Lundqvist C. et al. How are arrhythmias detected by implanted cardiac devices managed in Europe? Results of the European Heart Rhythm Association Survey. Europace 2015;17:1449–53.
    1. Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS.. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 2017;14:701–14.
    1. Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M. et al. Atrial high-rate episodes and stroke prevention. Europace 2017;19:169–79.
    1. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GH. et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:1241–6.
    1. Gillis AM, Morck M.. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol 2002;13:542–7.
    1. Glotzer TV, Hellkamp AS, Zimmerman J, Sweeney MO, Yee R, Marinchak R. et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003;107:1614–9.
    1. Tse HF, Lau CP.. Prevalence and clinical implications of atrial fibrillation episodes detected by pacemaker in patients with sick sinus syndrome. Heart 2005;91:362–4.
    1. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G. et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005;46:1913–20.
    1. Cheung JW, Keating RJ, Stein KM, Markowitz SM, Iwai S, Shah BK. et al. Newly detected atrial fibrillation following dual chamber pacemaker implantation. J Cardiovasc Electrophysiol 2006;17:1323–8.
    1. Orlov MV, Ghali JK, Araghi-Niknam M, Sherfesee L, Sahr D, Hettrick DA. et al. Asymptomatic atrial fibrillation in pacemaker recipients: incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol 2007;30:404–11.
    1. Mittal S, Stein K, Gilliam FR 3rd, Kraus SM, Meyer TE, Christman SA.. Frequency, duration, and predictors of newly-diagnosed atrial fibrillation following dual-chamber pacemaker implantation in patients without a previous history of atrial fibrillation. Am J Cardiol 2008;102:450–3.
    1. Healey JS, Martin JL, Duncan A, Connolly SJ, Ha AH, Morillo CA. et al. Pacemaker-detected atrial fibrillation in patients with pacemakers: prevalence, predictors, and current use of oral anticoagulation. Can J Cardiol 2013;29:224–8.
    1. Gonzalez M, Keating RJ, Markowitz SM, Liu CF, Thomas G, Ip JE. et al. Newly detected atrial high rate episodes predict long-term mortality outcomes in patients with permanent pacemakers. Heart Rhythm 2014;11:2214–21.
    1. Swiryn S, Orlov MV, Benditt DG, DiMarco JP, Lloyd-Jones DM, Karst E. et al. Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the registry of atrial tachycardia and atrial fibrillation episodes. Circulation 2016;134:1130–40.
    1. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C. et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009;2:474–80.
    1. Ziegler PD, Glotzer TV, Daoud EG, Ezekowitz MD, Singer DE, Koehler JL. et al. Incidence of newly detected atrial arrhythmias via implantable devices in patients with a prior history of stroke. Stroke 2009;40:E186–7.
    1. Ziegler PD, Glotzer TV, Daoud EG, Singer DE, Ezekowitz MD, Hoyt RH. et al. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. Am J Cardiol 2012;110:1309–14.
    1. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A. et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120–9.
    1. Shanmugam N, Boerdlein A, Proff J, Ong P, Valencia O, Maier SK. et al. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 2012;14:230–7.
    1. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY. et al. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J 2015;36:1660–8.
    1. Witt CT, Kronborg MB, Nohr EA, Mortensen PT, Gerdes C, Nielsen JC.. Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy. Heart Rhythm 2015;12:2368–75.
    1. Turakhia MP, Ziegler PD, Schmitt SK, Chang YC, Fan J, Than CT. et al. Atrial fibrillation burden and short-term risk of stroke case-crossover analysis of continuously recorded heart. Circ Arrhythm Electrophysiol 2015;8:1040–7.
    1. Charitos EI, Stierle U, Ziegler PD, Baldewig M, Robinson DR, Sievers HH. et al. A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions. Circulation 2012;126:806–14.
    1. Monfredi O, Boyett MR.. Sick sinus syndrome and atrial fibrillation in older persons—a view from the sinoatrial nodal myocyte. J Mol Cell Cardiol 2015;83:88–100.
    1. Wiesel J, Subclinical SM.. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:1351; author reply 1352–1353.
    1. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D. et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3:141–7.
    1. Nolker G, Mayer J, Boldt LH, Seidl K, Vand V, Massa T. et al. Performance of an implantable cardiac monitor to detect atrial fibrillation: results of the DETECT AF study. J Cardiovasc Electrophysiol 2016;27:1403–10.
    1. Dion F, Saudeau D, Bonnaud I, Friocourt P, Bonneau A, Poret P. et al. Unexpected low prevalence of atrial fibrillation in cryptogenic ischemic stroke: a prospective study. J Interv Card Electrophysiol 2010;28:101–7.
    1. Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ.. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology 2013;80:1546–50.
    1. Ritter MA, Kochhauser S, Duning T, Reinke F, Pott C, Dechering DG. et al. Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors. Stroke 2013;44:1449–52.
    1. Etgen T, Hochreiter M, Mundel M, Freudenberger T.. Insertable cardiac event recorder in detection of atrial fibrillation after cryptogenic stroke: an audit report. Stroke 2013;44:2007–9.
    1. Rojo-Martinez E, Sandin-Fuentes M, Calleja-Sanz AI, Cortijo-Garcia E, Garcia-Bermejo P, Ruiz-Pinero M. et al. [High performance of an implantable Holter monitor in the detection of concealed paroxysmal atrial fibrillation in patients with cryptogenic stroke and a suspected embolic mechanism]. Rev Neurol 2013;57:251–7.
    1. Christensen LM, Krieger DW, Hojberg S, Pedersen OD, Karlsen FM, Jacobsen MD. et al. Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study. Eur J Neurol 2014;21:884–9.
    1. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA. et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478–86.
    1. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA. et al. Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the cryptogenic stroke and underlying atrial fibrillation trial. Circ Arrhythm Electrophysiol 2016;9:e003333.
    1. Poli S, Diedler J, Hartig F, Gotz N, Bauer A, Sachse T. et al. Insertable cardiac monitors after cryptogenic stroke—a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. Eur J Neurol 2016;23:375–81.
    1. Israel C, Kitsiou A, Kalyani M, Deelawar S, Ejangue LE, Rogalewski A. et al. Detection of atrial fibrillation in patients with embolic stroke of undetermined source by prolonged monitoring with implantable loop recorders. Thromb Haemost 2017;117:1962–9.
    1. Reinke F, Bettin M, Ross LS, Kochhauser S, Kleffner I, Ritter M. et al. Refinement of detecting atrial fibrillation in stroke patients: results from the TRACK-AF Study. Eur J Neurol 2018;25:631–6.
    1. Pedersen KB, Madsen C, Sandgaard NCF, Diederichsen ACP, Bak S, Brandes A.. Subclinical atrial fibrillation in patients with recent transient ischemic attack. J Cardiovasc Electrophysiol 2018;29:707–14.
    1. Healey JS, Alings M, Ha A, Leong-Sit P, Birnie DH, de Graaf JJ. et al. Subclinical atrial fibrillation in older patients. Circulation 2017;136:1276–83.
    1. Reiffel JA, Verma A, Kowey PR, Halperin JL, Gersh BJ, Wachter R. et al. Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the REVEAL AF study. JAMA Cardiol 2017;2:1120–7.
    1. Nasir JM, Pomeroy W, Marler A, Hann M, Baykaner T, Jones R. et al. Predicting determinants of atrial fibrillation or flutter for therapy elucidation in patients at risk for thromboembolic events (PREDATE AF) study. Heart Rhythm 2017;14:955–61.
    1. Philippsen TJ, Christensen LS, Hansen MG, Dahl JS, Brandes A.. Detection of subclinical atrial fibrillation in high-risk patients using an insertable cardiac monitor. JACC Clin Electrophysiol 2017;3:1557–64.
    1. Romanov A, Martinek M, Purerfellner H, Chen S, De Melis M, Grazhdankin I. et al. Incidence of atrial fibrillation detected by continuous rhythm monitoring after acute myocardial infarction in patients with preserved left ventricular ejection fraction: results of the ARREST study. Europace 2018;20:263–70.
    1. Daley R, Mattingly TW, Holt CL, Bland EF, White PD.. Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951;42:566–81.
    1. Askey JM, Bernstein S.. The management of rheumatic heart disease in relation to systematic arterial embolism. Prog Cardiovasc Dis 1960;3:220–32.
    1. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB.. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973–7.
    1. Wolf PA, Abbott RD, Kannel WB.. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–8.
    1. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B.. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175–9.
    1. Preliminary report of the stroke prevention in atrial fibrillation study. N Engl J Med 1990;322:863–8.
    1. Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW.. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505–11.
    1. Hart RG, Benavente O, McBride R, Pearce LA.. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492–501.
    1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1–76.
    1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S. et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360–420.
    1. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL.. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35:183–7.
    1. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S. et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy. J Am Coll Cardiol 2007;50:2156–61.
    1. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546–54.
    1. Hughes M, Lip GY.. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008;99:295–304.
    1. Pisters R, Lane DA, Marin F, Camm AJ, Lip GY.. Stroke and thromboembolism in atrial fibrillation. Circ J 2012;76:2289–304.
    1. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ.. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864–70.
    1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ.. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Euro Heart Survey 2010;137:263–72.
    1. Singer DE, Chang Y, Borowsky LH, Fang MC, Pomernacki NK, Udaltsova N. et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013;2:e000250.
    1. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB. et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290:1049–56.
    1. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M. et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281–7a.
    1. Friberg L, Hammar N, Rosenqvist M.. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31:967–75.
    1. Lip GY, Frison L, Grind M.. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med 2008;264:50–61.
    1. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D. et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34:2464–71.
    1. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
    1. Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P. et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J 2016;37:1591–602.
    1. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL. et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444–51.
    1. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD. et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191–201.
    1. Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S. et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med 2019;380:1906–17.
    1. Markus HS, Hayter E, Levi C, Feldman A, Venables G, Norris J.. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial. Lancet Neurol 2015;14:361–7.
    1. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR. et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–16.
    1. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR. et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859–69.
    1. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M. et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018;379:1332–42.
    1. Group ES, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A.. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007;6:115–24.
    1. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62.
    1. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M. et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157–64.
    1. Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P. et al. Global prospective safety analysis of rivaroxaban. J Am Coll Cardiol 2018;72:141–53.
    1. Staerk L, Fosbol EL, Lip GYH, Lamberts M, Bonde AN, Torp-Pedersen C. et al. Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. Eur Heart J 2017;38:907–15.
    1. Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O. et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother 2017;3:28–36.
    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609–78.
    1. Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, John Camm A.. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471–4.
    1. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R. et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002;346:1854–62.
    1. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MR. et al. Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2017;38:1339–44.
    1. Mahajan R, Perera T, Elliott AD, Twomey DJ, Kumar S, Munwar DA. et al. Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis. Eur Heart J 2018;39:1407–15.
    1. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C. et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129:2094–9.
    1. Gorenek B, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV. et al. Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace 2017;19:1556–78.
    1. Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC. et al. Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. Am Heart J 2017;190:12–18.
    1. Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB. et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J 2017;189:137–45.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi